ArticleThe Lancet. Global health2022

Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries.

Marco Schäferhoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.